Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta‐analysis
Pooled result · Visceral fatResult — go to the resultSMD −0.72 95% CI −1.12 to −0.33Authors' conclusion
Liraglutide significantly and safely reduces visceral and ectopic liver fat irrespective of T2DM status, and reduces visceral fat provided adequate dosage and duration of therapy are ensured.
Study context
- Population
- Adults with or without T2D
- Participants
- 845 adults16 RCTs
- Comparison
- Liraglutide vs control
- Outcome
- Visceral fat
Methodological detailssubgroup analyses
- Subgroup analyses
Pooled result
As reported in the abstract
SMD
−0.72
95% CI −1.12 to −0.33
Liraglutidevs Control
SMD −0.72 (95% CI −1.12 to −0.33)
Further pooled results
| Outcome | Estimate | |
|---|---|---|
| Liver fat | SMD −0.78 (95% CI −1.24 to −0.32) | |
| BMI | weighted mean difference −1.44 (95% CI −1.95 to −0.92) | |
| Epicardial fat | SMD −0.74 (95% CI −1.82 to 0.34) | |
| −2−101Difference (linear scale) |
Visceral fat by subgroup (dosage, duration)
- Adequate dosage (≥1.8 mg/day) and treatment duration of 16 to 40 weeks were decisive for reducing visceral fat
Safety
- Mild gastrointestinal reactions were the main adverse event of liraglutide
Original publication
Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta‐analysis. Diabetes Obes Metab. Published 21 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →